Thumbnail Image
Item

Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (BEACON)

Zeeuw, Dick de
; 
Akizawa, Tadao
; 
Agarwal, Rajiv
; 
Audhya, Paul
; 
Bakris, George L.
; 
Chin, Melanie P.
; 
Krauth, Melissa
; 
Lambers Heerspink, Hiddo J.
; 
Meyer, Colin J.
; 
McMurray, John J.V.
... show 9 more
Citations
Google Scholar:
Lookup
Altmetric:
Author
Zeeuw, Dick de
Akizawa, Tadao
Agarwal, Rajiv
Audhya, Paul
Bakris, George L.
Chin, Melanie P.
Krauth, Melissa
Lambers Heerspink, Hiddo J.
Meyer, Colin J.
McMurray, John J.V.
Parving, Hans-Henrick
Pergola, Pablo E.
Remuzzi, Guiseppe
Toto, Robert D.
Vaziri, Nosratola D.
Wanner, Christoph
Warnock, David G.
Wittes, Janet T.
Chertow, Glenn M.
Abstract
Chronic kidney disease ( CKD ) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system ( RAAS ). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate ( eGFR ) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD.
Keywords
Clinical trial, trial design, bardoxolone methyl, nrf2, end-stage renal disease, cardiovascular death, chronic kidney disease, Diabetes mellitus, glomerular filtration rate
Date
2013
Type
Journal article
Journal
American Journal of Nephrology
Book
Volume
37
Issue
3
Page Range
212-222
Article Number
ACU Department
Collections
Faculty of Health Sciences - General
Show all metadata
URI
https://hdl.handle.net/20.500.14802/34504
Relation URI
DOI
10.1159/000346948
Source URL
Event URL
Open Access Status
License
File Access
Controlled
Notes